查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000848

单光子发射电脑断层扫描（SPECT）市场：按产品、检测器、应用和最终用户划分－2026-2032年全球市场预测

Single Photon Emission Computed Tomography Market by Product, Detector, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

单光子发射电脑断层扫描 (SPECT) 市场预计到 2025 年将达到 22.8 亿美元，到 2026 年将成长到 23.7 亿美元，到 2032 年将达到 30.2 亿美元，复合年增长率为 4.09%。

主要市场统计数据
基准年 2025 22.8亿美元
预计年份：2026年 23.7亿美元
预测年份 2032 30.2亿美元
复合年增长率 (%) 4.09%

为诊断领域的领导者提供当前 SPECT 趋势的简要概述，重点关注临床相关性、技术变革和采购考虑因素。

单光子发射电脑断层扫描（SPECT）仍然是核子医学的基石技术，它将功能性影像与循环系统、神经病学和肿瘤学等领域的广泛临床效用相结合。过去十年来的技术进步已使该技术从类比检测器范式转变为数位和固态架构，从而提高了计数灵敏度、空间解析度和工作流程整合度。这些进步，加上放射性药物物流、影像通讯协定和临床路径的变化，正在影响诊断中心和医院系统的应用和升级週期。

检测器、人工智慧重建和不断发展的临床工作流程方面的突破如何重新定义 SPECT 成像在诊断中的期望和筹资策略。

SPECT领域正经历一场变革，这主要得益于检测器创新、智慧软体和不断发展的临床工作流程的整合。新型检测器技术正推动系统从大型碘化钠晶体转向紧凑型碲化锌镉（CZT）和先进的固体感测器，从而提供独特的能量分辨率并缩短死时间。同时，影像重建演算法和人工智慧驱动的后处理正在提升病灶的检出和定量能力，并改变人们对诊断准确性和报告时间的预期。

我们将评估累积关税措施对 SPECT 系统製造商和医疗保健提供者的供应链、采购计划和筹资策略的影响。

美国近期采取的关税措施引发了全球医疗设备供应链的高度敏感性，对SPECT系统的製造商、经销商和最终用户都产生了累积影响。半导体检测器、精密机械零件和专用电子元件等组件极易受到关税带来的成本压力，这可能导致最终成本上升，并使医院和诊断中心的设备采购流程更加复杂。为此，製造商正在重新评估采购地点和供应合同，以降低风险并确保产品供应。

检测器技术、最终用户优先事项、产品架构和临床应用与采购和临床策略联繫起来的基于详细细分的见解。

检测器技术的细分揭示了临床应用优先事项的明显差异。先进的固体检测器，包括碲化镉锌检测器、锗半导体和硅光电倍增器，因其卓越的能量分辨率和计数灵敏度而备受青睐，尤其是在需要检测微小病灶的应用中。相较之下，碘化钠闪烁侦测器在成本效益和成熟工作流程至关重要的领域仍然占据主导地位，并在许多高通量诊断中心保持领先地位。检测器的这些差异不仅影响影像质量，还会影响维护需求、培训需求，甚至资本投资决策。

影响 SPECT 系统采购、部署和维护的美洲、欧洲、中东和非洲以及亚太地区的区域趋势和部署模式。

区域趋势显着影响SPECT系统的部署模式和策略重点，尤其是在美洲地区。该地区对先进心臟影像的需求集中，并已形成强大的供应商生态系统，能够迅速将创新的检测器技术转化为临床应用。在美洲地区，私人影像中心和医院网路通常优先考虑处理能力和综合服务合同，这为模组化系统升级和高性能检测器的应用创造了有利环境。法规环境和报销机制也进一步影响新技术在临床环境中的评估和应用方式。

竞争定位、卓越服务以及硬体创新者和软体开发商之间的伙伴关係如何影响 SPECT 供应商格局？

SPECT生态系统内的竞争动态主要由跨国影像设备製造商及专注于检测器创新及特定临床解决方案的专业公司所主导。大型成熟的医疗影像公司利用其全球服务网路和整合的产品系列，与医疗机构签订合同，并提供可预测的全生命週期支援。同时，小规模的专业公司则透过尖端的检测器技术、紧凑的机壳或软体主导的影像校正功能来脱颖而出。设备製造商和软体开发商之间的伙伴关係日益重要，这使得重建演算法和人工智慧辅助诊断工具能够不断迭代更新。

在实施 SPECT 技术时，医疗保健主管和供应商在协调采购、临床效用和供应链弹性方面面临的实际策略挑战。

计划投资SPECT技术的产业领导者应优先考虑模组化、供应链韧性和与临床需求的契合度，以做出面向未来的资本决策。在选择新系统时，决策者应要求具备灵活的升级路径，以便在不更换整个系统的情况下改进检测器和软体。这既能保护资本，又能根据不断变化的临床需求提升效能。筹资策略还应包含供应商多元化和合约保障措施，以降低关税和地缘政治因素造成的供应中断风险。

为了确保对 SPECT 技术有可靠和透明的了解，我们采用了严谨的多方面研究途径，结合了对临床医生的访谈、技术检验和二手文献的整合。

本研究采用多方面方法，交叉检验了关键相关人员的意见、精心挑选的二手资料以及技术检验。主要研究包括对临床终端使用者、影像物理学家、采购负责人和设备工程师进行结构化访谈，以了解他们对效能要求、操作挑战和服务期望的实际观点。此外，还咨询了监管专家，以解读核准流程和合规性对设备部署计画的影响，从而补充了这些定性见解。

对决定 SPECT 成功实施和长期临床价值的技术、操作和策略因素进行全面分析。

总而言之，SPECT 仍然是一种至关重要且适应性极强的成像技术，其短期前景将取决于检测器创新、软体带来的影像品质提升以及由营运重点和供应链趋势驱动的采购模式转变。积极将技术选择与临床应用案例结合、优先考虑模组化升级、完善的服务合约和实证实践的相关人员，将更有利于把技术进步转化为诊断信心和患者管理能力的显着提升。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 单光子发射电脑断层扫描（SPECT）市场：依产品分类

  • 双头
  • 单头
  • 三头

第九章：单光子发射电脑断层扫描（SPECT）市场（检测器类型划分）

  • Czt
  • 碘化钠闪烁
  • 固体的
    • 锗半导体
    • 硅光电倍增器

第十章 单光子发射电脑断层扫描（SPECT）市场：依应用领域划分

  • 循环系统
  • 神经病学
  • 肿瘤学

第十一章 单光子发射电脑断层扫描（SPECT）市场：依最终使用者划分

  • 诊断中心
  • 医院
    • 私立医院
    • 公立医院
  • 研究机构

第十二章 单光子发射电脑断层扫描（SPECT）市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 单光子发射电脑断层扫描（SPECT）市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 单光子发射电脑断层扫描（SPECT）市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国单光子发射电脑断层扫描（SPECT）市场

第十六章：中国的单光子发射电脑断层扫描（SPECT）市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Cyclotron Systems, Inc.
  • Agfa-Gevaert NV
  • Beijing Hamamatsu Photon Techniques Inc.
  • Bracco Imaging SpA
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • CardiArc, Ltd.
  • Cardinal Health, Inc.
  • Curium
  • DDD-Diagnostic A/S
  • Digirad Corporation
  • Gamma Medica, Inc.
  • GE HealthCare Technologies Inc.
  • Global Medical Solutions, Ltd.
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Koninklijke Philips NV
  • Lantheus Holdings, Inc.
  • Mediso Medical Imaging Systems Ltd.
  • MiE GmbH Medical Imaging Electronics
  • MILabs BV
  • Neusoft Medical Systems Co., Ltd.
  • Novartis AG
  • NTP Radioisotopes SOC Ltd
  • Nucare, Inc.
  • Parto Negar Persia Co.
  • Positron Corporation
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Spectrum Dynamics Medical Ltd.
Product Code: MRR-02026C4CB810

The Single Photon Emission Computed Tomography Market was valued at USD 2.28 billion in 2025 and is projected to grow to USD 2.37 billion in 2026, with a CAGR of 4.09%, reaching USD 3.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.28 billion
Estimated Year [2026] USD 2.37 billion
Forecast Year [2032] USD 3.02 billion
CAGR (%) 4.09%

A concise introduction to the current SPECT landscape highlighting clinical reliance, technological shifts, and procurement considerations for diagnostic leaders

Single Photon Emission Computed Tomography (SPECT) remains a cornerstone modality in nuclear medicine, combining functional imaging with widespread clinical utility across cardiology, neurology, and oncology. Technological evolution over the last decade has shifted the modality from analog detector paradigms toward digital and solid-state architectures, enabling improved count sensitivity, spatial resolution, and workflow integration. These advances are occurring in parallel with changes in radiopharmaceutical logistics, imaging protocols, and clinical pathways that collectively influence adoption and upgrade cycles in diagnostic centers and hospital systems.

Clinicians continue to rely on SPECT for myocardial perfusion imaging, brain perfusion assessments, and targeted oncologic studies where metabolic and receptor-based imaging complements anatomical techniques. As healthcare systems emphasize value-based outcomes and diagnostic efficiency, SPECT's adaptability-through diverse detector technologies and modular product configurations-supports a range of clinical use cases from high-volume cardiology labs to specialized research institutes. Consequently, procurement leaders and imaging directors must weigh clinical requirements, facility throughput, and lifecycle costs when planning equipment refreshes or new deployments.

Transitioning from established practice to innovation-led deployment requires careful alignment of technical performance with clinical protocols. Therefore, stakeholders should appraise detector options, head configurations, and service models in light of evolving clinical guidelines and operational priorities to ensure systems deliver measurable improvements in diagnostic confidence and patient throughput.

How detector breakthroughs, AI-driven reconstruction, and evolving clinical workflows are redefining diagnostic expectations and procurement strategies in SPECT imaging

The SPECT landscape is undergoing transformative shifts driven by convergence of detector innovation, software intelligence, and altered clinical workflows. New detector technologies are moving systems away from large-volume sodium iodide crystals toward compact cadmium zinc telluride and advanced solid-state sensors that offer intrinsic energy resolution and reduced dead time. Concurrently, image reconstruction algorithms and AI-enabled post-processing are enhancing lesion detectability and quantification, which is changing expectations for diagnostic accuracy and reporting timelines.

Operationally, hybrid imaging strategies and multimodality integration are reshaping how SPECT is positioned within diagnostic pathways; clinicians increasingly combine functional SPECT data with CT-derived attenuation correction and anatomical correlation, improving diagnostic confidence. At the same time, shifts in healthcare delivery-such as outpatient imaging consolidation and the proliferation of dedicated cardiac imaging centers-are altering procurement priorities toward systems that balance throughput with cost-efficiency. Supply chain dynamics and regulatory evolution are also prompting manufacturers and adopters to pursue diversified sourcing strategies and modular upgrade paths.

Taken together, these shifts create both opportunity and complexity: opportunities to enhance clinical utility and patient-centric workflows, and complexity in aligning technology selection with long-term serviceability, radiopharmaceutical availability, and evolving reimbursement models. Strategic planning must therefore reconcile rapid technological progress with sustainable operational models.

Assessing how cumulative tariff actions are reshaping supply chains, procurement timelines, and sourcing strategies for SPECT system manufacturers and healthcare providers

Recent tariff measures in the United States have introduced heightened sensitivity across global medical device supply chains, with cumulative implications for manufacturers, distributors, and end users of SPECT systems. Components such as semiconductor detectors, precision mechanical parts, and specialized electronics are vulnerable to tariff-induced cost pressures, which can increase landed costs and complicate capital procurement cycles for hospitals and diagnostic centers. In response, manufacturers are reassessing sourcing footprints and supply contracts to mitigate exposure while preserving product availability.

Consequently, many suppliers have accelerated localization of key components, established alternate supplier relationships, and adjusted logistics strategies to reduce tariff risk. These adaptations often entail nearshoring assembly operations, renegotiating supplier terms, and redesigning product architectures to use more readily sourced subsystems. Procurement teams are reacting by extending lead times in capital planning and prioritizing supplier stability and long-term service agreements over short-term price advantages.

From an operational standpoint, imaging centers may encounter longer procurement timelines and elevated acquisition costs that influence upgrade pacing and prioritization of high-throughput installations. Clinicians and administrators should therefore factor tariff-related supply chain uncertainty into capital planning, replacing assumptions of stable component availability with scenario-based procurement roadmaps that emphasize flexibility, lifecycle service support, and contractual protections against volatile input costs.

Deep segmentation-driven insights linking detector technologies, end-user priorities, product architectures, and clinical applications to procurement and clinical strategy

Detector technology segmentation reveals a clear divergence in clinical priorities: cadmium zinc telluride detectors and advanced solid-state options, including germanium semiconductors and silicon photomultipliers, are valued for superior energy resolution and count sensitivity, particularly in applications requiring small-lesion detection. By contrast, sodium iodide scintillation remains prevalent where cost efficiency and established workflows dominate, sustaining its presence in many diagnostic centers with large imaging volumes. These detector distinctions influence not only image quality but also service requirements, training needs, and capital allocation decisions.

End-user segmentation highlights differentiated procurement drivers across diagnostic centers, hospitals, and research institutes. Diagnostic centers prioritize throughput and cost-per-scan efficiency and therefore often favor systems with simplified workflows and rapid reconstruction. Hospitals, both private and public, balance clinical versatility with budgetary constraints; private hospitals may prioritize premium detectors and integrated service packages to support competitive positioning, whereas public hospitals frequently emphasize robust uptime, standardized protocols, and long-term maintenance contracts. Research institutes favor configurability and advanced detection technologies that enable protocol development and exploratory applications.

Product configuration also informs purchasing decisions: single-head systems appeal in space-constrained or low-volume settings, dual-head instruments offer balanced throughput and flexibility for general cardiology and oncology applications, and triple-head systems are selected where high sensitivity and faster acquisition are essential. Application segmentation into cardiology, neurology, and oncology continues to shape system requirements, with cardiology driving demand for rapid gated protocols, neurology emphasizing perfusion quantification, and oncology requiring compatibility with targeted tracers and quantitative workflows. Collectively, these segmentation layers determine the technical specifications, service models, and acquisition priorities that stakeholders must reconcile when selecting SPECT solutions.

Regional dynamics and adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence procurement, deployment, and serviceability of SPECT systems

Regional dynamics exert strong influence over adoption patterns and strategic priorities for SPECT systems, with the Americas exhibiting concentrated demand in advanced cardiac imaging and a robust vendor ecosystem that supports rapid clinical translation of detector innovations. In this region, private imaging centers and hospital networks often prioritize throughput and integrated service agreements, creating fertile ground for modular system upgrades and premium detector deployments. Regulatory environments and reimbursement frameworks further shape how new technologies are evaluated and adopted in clinical practice.

In Europe, the Middle East and Africa, the landscape is more heterogeneous; high-income European markets show steady uptake of advanced digital detectors and hybrid workflows, while markets across the Middle East and Africa are characterized by selective investments concentrated in tertiary hospitals and specialty centers. These geographies often emphasize reliability and long-term serviceability, given the logistical complexities of cross-border parts supply. Meanwhile, Asia-Pacific demonstrates rapid modernization in imaging infrastructure, driven by expanding middle-class healthcare demand, investment in specialized cardiac and oncologic centers, and local manufacturing initiatives that can lower acquisition barriers for advanced detector systems.

Across all regions, localized factors such as radiopharmaceutical availability, training ecosystems, and healthcare policy priorities shape how facilities prioritize upgrades and deploy SPECT systems. As a result, regional strategy must integrate clinical needs, supply chain resilience, and regulatory compliance to optimize deployment and ensure sustainable operations.

How competitive positioning, service excellence, and partnerships between hardware innovators and software developers are shaping the SPECT vendor landscape

Competitive dynamics in the SPECT ecosystem are governed by a mix of multinational imaging manufacturers and specialized firms that emphasize detector innovation or niche clinical solutions. Large, established medical imaging companies continue to leverage global service networks and integrated product portfolios to secure institutional contracts and deliver predictable lifecycle support, while smaller specialists differentiate through cutting-edge detector technologies, compact form factors, or software-driven image enhancement. Partnerships between device manufacturers and software developers are increasingly important, enabling iterative updates to reconstruction algorithms and AI-supported diagnostic aids.

Service and aftermarket support represent a decisive competitive axis: vendors that offer comprehensive training programs, predictive maintenance, and rapid parts availability tend to secure longer-term contracts with hospitals and diagnostic chains. Additionally, collaborative initiatives with radiopharmaceutical suppliers and clinical research organizations strengthen a supplier's value proposition by facilitating multi-center studies and protocol standardization. Capital equipment procurement committees and imaging directors therefore evaluate vendors not only on device performance but on the total cost of ownership, upgrade pathways, and demonstrated clinical outcomes.

Innovation pipelines focus on detector miniaturization, enhanced energy discrimination, and software platforms that improve quantitative reporting. This combination of hardware and software advancement provides new entrants with avenues to challenge incumbent offerings, while incumbents invest in acquisition, partnership, and internal R&D programs to maintain relevance. Ultimately, competitive success depends on aligning technical differentiation with dependable service models and evidence of clinical impact.

Actionable strategic imperatives for healthcare executives and vendors to align procurement, clinical utility, and supply chain resilience when adopting SPECT technologies

Industry leaders planning investments in SPECT technology should prioritize modularity, supply chain resilience, and clinical alignment to future-proof capital decisions. When specifying new systems, decision-makers should require flexible upgrade paths that allow detector or software improvements without full system replacement, thereby protecting capital while enabling performance enhancements as clinical needs evolve. Procurement strategies must also incorporate supplier diversification and contractual protections to mitigate tariff-driven and geopolitical supply disruptions.

Clinically, organizations should align acquisition criteria with high-impact applications: prioritize systems that demonstrably improve diagnostic confidence in cardiology, neurology, or oncology workflows and that integrate seamlessly with PACS and reporting infrastructures. Investing in staff training and protocol harmonization enhances the clinical value of advanced detectors and reconstruction software, ensuring that improved imaging performance translates into better patient management. From an operational perspective, emphasize total lifecycle support agreements and spare-part logistics to maximize uptime and predictable operating costs.

Finally, collaboration with industry partners on pilot studies and phased rollouts can de-risk adoption while generating local evidence of clinical and operational benefits. By combining flexible technical specifications with robust service frameworks and evidence-generating partnerships, leaders can secure imaging assets that deliver sustained clinical value and operational resilience.

A rigorous multi-method research approach combining clinician interviews, technical validation, and secondary literature synthesis to ensure reliable and transparent insights into SPECT technologies

This research was developed using a multi-method approach that triangulates primary stakeholder inputs with curated secondary sources and technical validation. Primary research included structured interviews with clinical end users, imaging physicists, procurement officers, and device engineers to capture frontline perspectives on performance requirements, operational challenges, and service expectations. These qualitative insights were supplemented by consultations with regulatory specialists to interpret approval pathways and compliance implications that affect device deployment timelines.

Secondary research encompassed peer-reviewed literature, clinical guidelines, manufacturer technical specifications, and publicly available regulatory filings to establish a robust evidence base on detector performance characteristics, imaging protocols, and application-specific requirements. Quantitative cross-checks were performed where feasible through anonymized procurement case studies and device lifecycle records provided by participating institutions. Throughout the process, data validation techniques such as source triangulation, consistency checks, and expert panel review were applied to ensure analytic rigor and mitigate potential bias.

The methodology emphasizes transparency and reproducibility: assumptions are documented, interview instruments are archived, and the analytical framework is designed to accommodate updates as new clinical evidence and technological developments emerge. Stakeholders seeking methodological clarification or bespoke analysis were invited to engage directly with the research team for tailored validation exercises.

Concluding synthesis of technological, operational, and strategic factors that will determine successful SPECT adoption and long-term clinical value

In conclusion, SPECT remains a vital and adaptable imaging modality whose near-term trajectory is defined by detector innovation, software-enabled image quality gains, and shifting procurement paradigms driven by operational priorities and supply chain dynamics. Stakeholders that proactively align technical selections with clinical use cases-prioritizing modular upgrades, robust service agreements, and evidence generation-will be best positioned to translate technological advances into measurable improvements in diagnostic confidence and patient throughput.

Tariff-related supply chain disruptions and regional heterogeneity underscore the need for flexible sourcing strategies and scenario-based procurement planning. Meanwhile, the competitive landscape rewards vendors that couple hardware differentiation with dependable aftermarket support and collaborative evidence-generation efforts. As the clinical community continues to demand higher resolution, faster acquisitions, and quantitative outputs, the combination of advanced detectors and intelligent reconstruction will shape the next wave of SPECT deployments.

Moving forward, organizations should balance innovation adoption with operational resilience, ensuring that investments in SPECT technology are underpinned by training, standardized protocols, and supplier relationships that support long-term clinical and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Single Photon Emission Computed Tomography Market, by Product

  • 8.1. Dual Head
  • 8.2. Single Head
  • 8.3. Triple Head

9. Single Photon Emission Computed Tomography Market, by Detector

  • 9.1. Czt
  • 9.2. Nai Scintillation
  • 9.3. Solid State
    • 9.3.1. Germanium Semiconductor
    • 9.3.2. Silicon Photomultiplier

10. Single Photon Emission Computed Tomography Market, by Application

  • 10.1. Cardiology
  • 10.2. Neurology
  • 10.3. Oncology

11. Single Photon Emission Computed Tomography Market, by End User

  • 11.1. Diagnostic Centers
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutes

12. Single Photon Emission Computed Tomography Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Single Photon Emission Computed Tomography Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Single Photon Emission Computed Tomography Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Single Photon Emission Computed Tomography Market

16. China Single Photon Emission Computed Tomography Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Cyclotron Systems, Inc.
  • 17.6. Agfa-Gevaert N.V.
  • 17.7. Beijing Hamamatsu Photon Techniques Inc.
  • 17.8. Bracco Imaging S.p.A.
  • 17.9. Bruker Corporation
  • 17.10. Canon Medical Systems Corporation
  • 17.11. CardiArc, Ltd.
  • 17.12. Cardinal Health, Inc.
  • 17.13. Curium
  • 17.14. DDD-Diagnostic A/S
  • 17.15. Digirad Corporation
  • 17.16. Gamma Medica, Inc.
  • 17.17. GE HealthCare Technologies Inc.
  • 17.18. Global Medical Solutions, Ltd.
  • 17.19. Hitachi, Ltd.
  • 17.20. Hologic, Inc.
  • 17.21. Koninklijke Philips N.V.
  • 17.22. Lantheus Holdings, Inc.
  • 17.23. Mediso Medical Imaging Systems Ltd.
  • 17.24. MiE GmbH Medical Imaging Electronics
  • 17.25. MILabs B.V.
  • 17.26. Neusoft Medical Systems Co., Ltd.
  • 17.27. Novartis AG
  • 17.28. NTP Radioisotopes SOC Ltd
  • 17.29. Nucare, Inc.
  • 17.30. Parto Negar Persia Co.
  • 17.31. Positron Corporation
  • 17.32. Shimadzu Corporation
  • 17.33. Siemens Healthineers AG
  • 17.34. Spectrum Dynamics Medical Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DUAL HEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DUAL HEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DUAL HEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SINGLE HEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SINGLE HEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SINGLE HEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY TRIPLE HEAD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY TRIPLE HEAD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY TRIPLE HEAD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CZT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CZT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CZT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NAI SCINTILLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NAI SCINTILLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NAI SCINTILLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GERMANIUM SEMICONDUCTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GERMANIUM SEMICONDUCTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GERMANIUM SEMICONDUCTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SILICON PHOTOMULTIPLIER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SILICON PHOTOMULTIPLIER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SILICON PHOTOMULTIPLIER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 124. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 145. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 152. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY DETECTOR, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY SOLID STATE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)